> 首页 > 产品 > 一抗 > 其他 > Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab)

Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab)

Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab) is 95.07%, determined by SEC-HPLC.
Reozalimab bound to PD-1 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Reozalimab bound to huPD-1-His, and the EC50 was 0.004 nM.
Reozalimab bound to PD-L1 protein, and then rebounded to secondary antibodies(Anti-human-κ+λ-HRP) , and read OD450. As shown in fig, Reozalimab bound to huPD-L1-Fc, and the EC50 was 0.015 nM.
Reozalimab bound to huPD-1-Jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Reozalimab bound to huPD-1-Jurkat cells, and the EC50 was 0.990 nM.
Reozalimab bound to huPD-L1-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Reozalimab bound to huPD-L1-CHO-K cells, and the EC50 was 2.237 nM.
Co-incubation of Reozalimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Reozalimab was able to block the PD-1/PD-L1 signaling pathway, and the EC50 was 0.728 nM.
The detected weight of Anti-PD-1 & PD-L1 Reference Antibody (Reozalimab) is 143.56 kDa.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q15116 & Q9NZQ7
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-like

Additional Information
Target/Specificity	PDCD1 / PD-1 / CD279,B7-H1 / PD-L1 / CD274
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.